1. For several reasons, a better bio-material needed for ortho implant and Si3N4 is the best one at this moment. 2. AMDA is only medical grade Si3N4 product manufacturer worldwide. More and more OEM accepting this technology.
3. Most recent 510K for CsC product line - FDA just asked 24 months clinical trial data after first feed back. FDA didn't say NO rather interested to see more data. 24 months data will be available in 3 months.
4. AMDA already has some other Si3N4 product line approved by FDA and sales are increasing at good space.
5. Cash position is good enough to continue business. 6. Si3N4 is a disrupting technology in ortho implant market. 7. Market cap too low ( undervalued)